Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Biomarkers Shift Treatment Paradigm in CLL

June 14th 2017

With changing treatment paradigms, particularly the use of oral targeted agents, predictive value and use of prognostic factors to determine treatment choice are shifting in CLL.

Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLL

June 13th 2017

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses the outcomes of patients with high-risk chronic lymphocytic leukemia (CLL) and how ibrutinib (Imbruvica) targets these patients.

Byrd Highlights Ibrutinib's Continued Progress in CLL

June 12th 2017

John C. Byrd, MD, sheds light on the game-changing efficacy of ibrutinib in chronic lymphocytic leukemia.

Dr. Rai on the Treatment Paradigm for CLL

June 8th 2017

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).

Marrow Clearance With Concurrent CAR T-Cells, Ibrutinib in Resistant CLL

June 7th 2017

Concurrent treatment with CTL-119 cell therapy and ibrutinib (Imbruvica) led to complete marrow clearance of leukemic cells in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia, results of a pilot study showed.

Dr. Sharman on the Phase III Results of the GENUINE Study in CLL

June 5th 2017

Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).

Lenalidomide Consolidation OS Plateau Intrigues in CLL

June 4th 2017

Induction therapy with fludarabine and rituximab followed by lenalidomide consolidation therapy (FR-L) demonstrated a distinct plateau in overall survivalbeyond that seen with FR or FR plus cyclophosphamide (FCR) alone for patients with symptomatic, untreated non-del(11q) chronic lymphocytic leukemia.

Ublituximab/Ibrutinib Shows High ORR for High-Risk CLL

June 4th 2017

The combination of ublituximab and ibrutinib demonstrated an objective response rate of 78% for patients with previously treated high-risk chronic lymphocytic leukemia.

Leukemia Researcher Sees Exciting Prospects for New Targeted Agents

June 1st 2017

Jeff Sharman, MD, discusses the prospects for progress in targeting elements of the BCR pathway.

Expert Explains Next Steps With Advancing CLL Care

May 23rd 2017

Richard R. Furman, MD, discusses the continued evolution of the field of chronic lymphocytic leukemia and how physicians decide on the optimal treatment sequence for their patients.

Dr. Parikh on the Significance of the CLL-IPI

May 23rd 2017

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).

CLL-IPI an Essential Tool for Determining Treatment Approaches

May 17th 2017

Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.

Dr. Furman on Utility of Prognostic Markers in CLL

May 12th 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the use of prognostic markers in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Jain Discusses Treatment of Richter's Transformation in CLL

May 8th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

Frontline CLL Care Continues to Evolve

May 8th 2017

Steven Coutre, MD, discusses ongoing efforts to enhance frontline outcomes for patients with CLL.

Dr. Wierda on the Need for Continuous Treatment for CLL

May 5th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for continuous treatments for patients with chronic lymphocytic leukemia (CLL).

Dr. Leblond Discusses Treatment After Relapse in CLL

May 2nd 2017

Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.

Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL

April 26th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Complete Response to Chemo Critical in CLL Patients Who Develop Hodgkin Lymphoma

April 24th 2017

Achieving a complete response following ABVD chemotherapy offered the best chance for survival for patients with chronic lymphocytic leukemia who developed Hodgkin lymphoma following Richter transformation, according to a retrospective study published in the American Journal of Hematology.

Ibrutinib Better Than Bendamustine for OS in CLL, Indirect Comparison Suggests

April 21st 2017

Results of a systematic literature search published online in Clinical Lymphoma, Myeloma & Leukemia showed that ibrutinib was associated with superior survival and fewer adverse events compared with bendamustine in patients with chronic lymphocytic leukemia.